Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
The firm is developing a rapid point-of-care diagnostic system focused on combating antimicrobial resistance.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
A US National Institute of Allergy and Infectious Diseases-led team sequenced the exome of a young girl with recurrent, severe infections to uncover the gene variant.
The firm expects that revenues from ePlex installations at US customer sites will positively impact its financial results for the second half of 2017.
The test, which runs directly from a patient nasopharyngeal swab, is the fifth assay on the firm's sample-to-result molecular diagnostics platform.
CEO Hany Massarany said that 2017 will be a pivotal year for the company as it expects to launch the ePlex sample-to-answer system in the US.
GenMark's CEO said that the firm continues to focus on growing the ePlex instrument's global reach and expanding its menu.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.
Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.
In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.